ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 153 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,534,000 | -35.7% | 369,802 | -2.6% | 0.01% | -37.5% |
| Q2 2023 | $3,939,000 | +153.1% | 379,802 | +97.5% | 0.01% | +166.7% |
| Q1 2023 | $1,556,000 | -48.7% | 192,323 | -0.1% | 0.00% | -57.1% |
| Q4 2022 | $3,031,000 | +229.8% | 192,424 | +229.8% | 0.01% | +250.0% |
| Q3 2022 | $919,000 | +9.4% | 58,353 | -2.9% | 0.00% | 0.0% |
| Q2 2022 | $840,000 | -23.1% | 60,092 | -5.1% | 0.00% | 0.0% |
| Q1 2022 | $1,092,000 | +10.6% | 63,299 | -6.7% | 0.00% | 0.0% |
| Q4 2021 | $987,000 | -19.6% | 67,879 | -0.6% | 0.00% | -33.3% |
| Q3 2021 | $1,228,000 | +8.5% | 68,278 | +5.9% | 0.00% | 0.0% |
| Q2 2021 | $1,132,000 | -30.3% | 64,478 | 0.0% | 0.00% | -40.0% |
| Q1 2021 | $1,624,000 | +335.4% | 64,478 | +12.1% | 0.01% | +150.0% |
| Q4 2020 | $373,000 | +143.8% | 57,500 | -3.7% | 0.00% | +100.0% |
| Q3 2020 | $153,000 | +35.4% | 59,685 | -14.3% | 0.00% | 0.0% |
| Q2 2020 | $113,000 | +56.9% | 69,635 | 0.0% | 0.00% | – |
| Q1 2020 | $72,000 | -36.3% | 69,635 | +16.8% | 0.00% | -100.0% |
| Q4 2019 | $113,000 | +73.8% | 59,635 | 0.0% | 0.00% | – |
| Q3 2019 | $65,000 | -50.0% | 59,635 | +1.0% | 0.00% | -100.0% |
| Q2 2019 | $130,000 | -63.4% | 59,073 | -0.2% | 0.00% | -50.0% |
| Q1 2019 | $355,000 | -30.7% | 59,203 | -14.7% | 0.00% | -50.0% |
| Q4 2018 | $512,000 | -52.9% | 69,406 | -7.3% | 0.00% | -50.0% |
| Q3 2018 | $1,087,000 | -17.3% | 74,834 | +13.7% | 0.01% | -20.0% |
| Q2 2018 | $1,315,000 | -3.6% | 65,816 | -15.4% | 0.01% | -9.1% |
| Q1 2018 | $1,364,000 | -57.3% | 77,816 | -40.0% | 0.01% | -57.7% |
| Q4 2017 | $3,196,000 | -14.1% | 129,616 | -10.1% | 0.03% | -18.8% |
| Q3 2017 | $3,722,000 | -4.7% | 144,159 | +0.1% | 0.03% | -8.6% |
| Q2 2017 | $3,904,000 | -9.0% | 143,959 | +0.0% | 0.04% | -14.6% |
| Q1 2017 | $4,291,000 | +153.8% | 143,891 | +131.0% | 0.04% | +127.8% |
| Q4 2016 | $1,691,000 | +27.2% | 62,288 | +20.0% | 0.02% | +20.0% |
| Q3 2016 | $1,329,000 | +38.6% | 51,886 | 0.0% | 0.02% | +25.0% |
| Q2 2016 | $959,000 | – | 51,886 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |